Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E3810 (rabeprazole) 10 mg once vs twice daily for maintenance therapy in PPI‑resistant reflux esophagitis
jRCT2080222489Phase 3Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rabeprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (3 arms), sponsored by EA Pharma Co., Ltd. Started May 2014; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on jRCT2080222489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222489.